SCHEMBL379504

SCHEMBL379504

Cc1cccnc1CNc1nccc2scc(-c3ccccc3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.47
MAPK1 P28482 1/20 0.47
NOD1 Q9Y239 1/20 0.47
CCNC P24863 1/20 0.41
CDK8 P49336 1/20 0.41
KDR P35968 7/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 1/20 0.40
ESR1 P03372 3/20 0.38
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
PIP4K2C Q8TBX8 1/20 0.37
KCNH2 Q12809 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379470 0.83 IGF1R (0.42) KDRKMT2AMEN1NPC1RAB9A
SCHEMBL2368709 0.83 MAPK1 (0.69) TNFMAPK1NOD1CCNCCDK8
SCHEMBL379865 0.82 ESR1 (0.55) TNFMAPK1NOD1CCNCCDK8
SCHEMBL379387 0.81 TNF (0.69) TNFMAPK1NOD1AURKBPIP4K2C
SCHEMBL379757 0.79 CCNC (0.47) TNFMAPK1NOD1CCNCCDK8
SCHEMBL380011 0.78 UTS2R (0.53) TNFMAPK1NOD1KMT2AMEN1
SCHEMBL379745 0.77 EED (0.49) TNFMAPK1NOD1KMT2AMEN1
SCHEMBL4946829 0.76 PDE11A (0.49) TNFMAPK1NOD1CCNCCDK8
SCHEMBL379602 0.74 PDE11A (0.47) TNFMAPK1NOD1CCNCCDK8
SCHEMBL379800 0.72 KDM4E (0.43) TNFMAPK1NOD1CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 TNF 953/4885MAPK1 158/4885NOD1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.